• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

    8/17/23 6:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMAB alert in real time by email
    • Significant progress made year-to-date on key clinical assets:

      ‐         Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023

      ‐         Givastomig (Claudin 18.2 x 4-1BB bispecific antibody): Topline Phase 1 data with promising early efficacy signals, including patients with low levels of Claudin 18.2 tumor expression. Data to be presented at ESMO 2023
    • Eftansomatropin alfa (long-acting recombinant human growth hormone): Phase 3 pivotal study evaluating weekly injection of eftansomatropin alfa met the primary endpoint of annualized height velocity at week 52 and demonstrated non-inferiority to Norditropin®, administered by daily injection. A BLA filing is being planned for 2024
    • Strong cash position of RMB3.0 billion (US$414.6 million) as of June 30, 2023, to support execution of the Company's strategic plan
    • The Board of Directors authorized a new stock repurchase program of up to US$40 million to enhance long-term shareholder value
    • Conference call planned for August 17, 2023 at 8:00 a.m. EST

    ROCKVILLE, Md. and SHANGHAI, Aug. 17, 2023 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology, today announced its financial results for the six months ended June 30, 2023, and provided key business updates.

    I-MAB Logo (PRNewsfoto/I-Mab Biopharma)

    I-Mab has made significant progress in advancing its pipeline of innovative assets over the last eight months.

    "2023 is off to a great start with promising early results from our two lead oncology programs, uliledlimab, and givastomig, coupled with new, positive Phase 3 eftansomatropin alfa results, thanks to the diligent efforts of our employees. As we move forward, we plan to focus on three strategic pillars: prioritizing two promising clinical assets in oncology to advance in the US, maintaining our strong balance sheet, and focusing on establishing a new operating model to become a US-based global biotech company," said Raj Kannan, Chief Executive Officer of I-Mab.

    H1 2023 Key Clinical Program Highlights

    Uliledlimab (CD73 mAb): Encouraging clinical and translational data presented at ASCO 2023

    Uliledlimab is a highly differentiated CD73 antibody which can completely inhibit CD73 enzymatic activity without causing the aberrant pharmacological property known as the "hook effect." Results from an ongoing Phase 2 study of uliledlimab in combination with toripalimab, a PD-1 inhibitor, showed a favorable safety profile and an encouraging objective response rate (ORR) of 31% (21/67) in the overall population regardless of CD73 and PD-L1 expression. In this study, without concomitant chemotherapy, in patients whose tumors expressed higher levels of CD73 and had a PD-L1 tumor proportion score (TPS) of >1%, the observed ORR was 63% (10/16). 

    Next steps: The clinical program is currently focused on non-small cell lung cancer (NSCLC) and ovarian cancer. Enrollment in the Phase 2 study of uliledlimab with toripalimab for patients with ovarian cancer is ongoing in China. In the US, I-Mab plans to submit an IND for uliledlimab in combination with chemotherapy and checkpoint inhibitors in newly diagnosed patients with advanced NSCLC in H1 2024.

    Givastomig (Claudin 18.2 x 4-1BB bispecific Ab): Phase 1 trial data and publication highlight potential for a differentiated program

    Encouraging initial Phase 1 results: Givastomig was designed as a bispecific antibody to target Claudin 18.2-positive tumor cells and stimulate pro-immune 4-1BB signaling. Phase 1 dose escalation has reached the highest planned dose level. Most treatment-related adverse events have been low-grade. In this study, encouraging findings of monotherapy efficacy were observed, including in tumors with lower levels of Claudin 18.2 expression, in patients with previously treated cancer that has relapsed or progressed after prior standard treatments.

    Preclinical data on this program were published in the July 2023 issue of the Journal of Immunotherapy of Cancer, and the Phase 1 monotherapy dose escalation data were selected for presentation at the European Society of Medical Oncology (ESMO) in October 2023. An expansion cohort of patients with Claudin 18.2 positive gastric, gastroesophageal junction (GEJ), and esophageal cancer whose disease has progressed after previous treatment is enrolling, and interim results are expected in H1 2024.

    Based upon these encouraging signals, dose escalation is expected to begin in combination with standard chemotherapy and immunotherapy regimens for patients with treatment naïve gastric, GEJ, and esophageal cancer in the US, Japan, and China in H1 2024.

    The program is being developed in collaboration with ABL Bio.

    TJ-L14B/ABL503 (PD-L1 x 4-1BB bispecific antibody): Phase 1 Dose Expansion initiated in H1 2023

    TJ-L14B/ABL503 was designed to treat PD-(L)1 antibody-resistant tumors. The antibody acts by inducing conditional activation of 4-1BB when it binds to its target, PD-L1. A Phase 1 dose-escalation study is underway in patients with progressive, locally advanced or metastatic solid tumors who are relapsed or refractory following prior lines of treatment. A preliminary efficacy signal has been observed, and a maximally tolerated dose (MTD) has not yet been reached. The dose expansion portion of the Phase 1 study is underway in the US and South Korea. The program is also being developed in collaboration with ABL Bio.

    New Data: Eftansomatropin alfa (long-acting recombinant human growth hormone)

    I-Mab today announced positive topline results from its multi-center, randomized, open-label, active-controlled pivotal phase 3 study (CTJ101PGHD301) evaluating the efficacy and safety of eftansomatropin alfa in children with growth hormone deficiency.

    The study met its primary endpoint of annualized height velocity (AHV) at week 52 and demonstrated that eftansomatropin alfa was non-inferior to Norditropin®. Eftansomatropin alfa was given by weekly injection vs. Norditropin® given by daily injection. The mean AHV was 10.76 (cm/year) for eftansomatropin alfa vs. 10.28 (cm/year) for Norditropin®, with a difference of 0.47 [95% CI -0.06,1.00] and non-inferiority p-value <0.0001. Eftansomatropin alfa was well tolerated and no drug discontinuation was reported due to treatment related adverse events. The safety profile of eftansomatropin alfa was comparable to Norditropin®. The Company is planning to file a BLA submission in China in 2024.

    Commercial partnership with Jumpcan for product launch and commercialization of eftansomatropin alfa in China is ongoing.

    Felzartamab (CD38 antibody): Phase 3 Multiple Myeloma Results Expected in 2024

    Felzartamab is in development for the treatment of multiple myeloma (MM). Clinical studies have been conducted in second- and third-line treatment settings. The randomized, open-label, parallel-controlled Phase 3 study of felzartamab in combination with lenalidomide and dexamethasone as a second-line treatment for MM with progression-free survival (PFS) as the primary endpoint is ongoing with a projected read-out in 2024, followed by planned BLA submission.

    Lemzoparlimab (CD47 antibody): Phase 3 trial underway in China

    The development of lemzoparlimab, focused on China, has the potential to be the first-in-class CD47 antibody for hematologic malignancies in this market. The Phase 3 program is evaluating lemzoparlimab in combination with azacytidine (AZA) as first-line treatment for patients with newly diagnosed higher-risk myelodysplastic syndrome (MDS). Enrollment in the Phase 3 trial was initiated in April 2023. The Company will continue to review Phase 2 clinical follow-up data in the higher risk-MDS study and analyze details from other trials evaluating other CD47-targeting agents as they are released, to inform the Company's decisions on the future steps for the program.

    Corporate Development

    • In August 2023, the Board of Directors of the Company authorized a new share repurchase program under which the Company may repurchase up to US$40 million of American depository shares ("ADSs") or ordinary shares in aggregate over the next 12 months. The timing and dollar amount of share repurchase transactions will be subject to the applicable U.S. Securities and Exchange Commission rule requirements. The Company's Board of Directors will review the implementation of share repurchases periodically and may authorize adjustment of its terms and size.
    • Proprietary position for uliledlimab fortified with Tracon and KG Bio resolutions.

      ‐       The positive outcome in arbitration relating to the collaboration agreement with Tracon Pharmaceuticals, Inc. (Tracon) confirms that Tracon has no rights to share any future economics with I-Mab for uliledlimab.

      ‐       In June 2023, the Company terminated the first negotiation agreement with Kalbe Genexine Biologics (KG Bio), pursuant to which KG Bio no longer has a right of first negotiation for the exclusive right to commercialize uliledlimab in Southeast Asia and other territories.

    First-Half 2023 Financial Results

    Cash Position

    As of June 30, 2023, the Company had cash, cash equivalents, restricted cash, and short-term investments of RMB3.0 billion (US$414.6 million), compared with RMB3.5 billion (US$489.0 million) as of December 31, 2022.

    Net Revenues

    Total net revenues for the six months ended June 30, 2023 were RMB19.7 million (US$2.7 million), compared with RMB51.9 million (US$7.2 million) for the comparable period in 2022. Revenues consisted of revenues recognized in connection with the strategic collaboration with AbbVie and revenues generated from the supply of investigational products to AbbVie Inc (Abbvie) and Human Immunology Biosciences, Inc. for the six months ended June 30, 2022 and 2023, respectively.

    Research & Development Expenses

    Research and development expenses for the six months ended June 30, 2023 were RMB446.4 million (US$61.6 million), compared with RMB452.6 million (US$62.4 million) for the comparable period in 2022. The decrease was primarily due to the reduced payroll and share-based compensation expenses, partially offset by a slight increase in Chemistry, Manufacturing, and Controls service fees. Share-based compensation expense was RMB46.8 million (US$6.5 million) for the six months ended June 30, 2023, compared with RMB77.6 million (US$10.7 million) for the comparable period in 2022. 

    Administrative Expenses

    Administrative expenses for the six months ended June 30, 2023 were RMB245.0 million (US$33.8 million), compared with RMB392.5 million (US$54.1 million) for the comparable period in 2022. The decrease was primarily due to lower payroll expenses and share-based compensation expenses for management personnel and reduced expenses for professional services. Share-based compensation expense was RMB88.0 million (US$12.1 million) for the six months ended June 30, 2023, compared with RMB119.3 million (US$16.5 million) for the comparable period in 2022.

    Other Expenses, Net

    Net other expenses for the six months ended June 30, 2023 were RMB71.7 million (US$9.9 million), compared with RMB51.9 million (US$7.2 million) for the comparable period in 2022. The increase was primarily caused by the higher unrealized exchange losses due to the significant fluctuation in the exchange rate of the Renminbi (RMB) against the U.S. dollars in 2023.

    Equity in Loss of Affiliates

    Equity in loss of affiliates for the six months ended June 30, 2023 was RMB59.6 million (US$8.2 million), compared with RMB181.0 million (US$25.0 million) for the comparable period in 2022. The loss was mainly recognized in relation to the Company's affiliate, I-Mab Biopharma (Hangzhou) Co., Ltd.

    Net Loss

    Net loss for the six months ended June 30, 2023 was RMB772.8 million (US$106.6 million), compared with RMB1,046.9 million (US$144.4 million) in the comparable period in 2022. Net loss per share attributable to ordinary shareholders as of June 30, 2023 was RMB4.04 (US$0.56), compared with RMB5.54 (US$0.76) for the comparable period in 2022. Net loss per ADS attributable to ordinary shareholders as of June 30, 2023 was RMB9.29 (US$1.28), compared with RMB12.74 (US$1.76) for the comparable period in 2022. As of June 30, 2023, I-Mab has 190,033,689 shares outstanding.

    Non-GAAP Net Loss

    Non-GAAP adjusted net loss, which excludes share-based compensation expenses, for the six months ended June 30, 2023 was RMB634.2 million (US$87.5 million), compared with RMB848.0 million (US$116.9 million) for the comparable period in 2022. Non-GAAP adjusted net loss per share attributable to ordinary shareholders for the six months ended June 30, 2023 was RMB3.31 (US$0.46), compared with RMB4.49 (US$0.62) for the comparable period in 2022. Non-GAAP adjusted net loss per ADS attributable to ordinary shareholders for the six months ended June 30, 2023 was RMB7.61 (US$1.05), compared with RMB10.33 (US$1.42) for the comparable period in 2022. 

    Conference Call Information

    Investors and analysts are invited to join the conference call at 8:00 a.m. EST on August 17, 2023 via Zoom:

    https://i-mabbiopharma.zoom.us/j/87349766033?pwd=bFhVejFDS1dHeWw3eklaeW1JcFhpUT09

    Meeting ID: 873 4976 6033

    Password: 194422

    Note that call participants can register in advance via the above link to streamline the login process. 

    About I-Mab

    I-Mab (Nasdaq: IMAB) is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology. I-Mab's innovative pipeline is driven by internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn, Twitter, and WeChat.

    I-Mab Forward-Looking Statements

    This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident," and similar statements. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: I-Mab's transition and its new operating model to become a U.S.-based global biotech; I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to attract and maintain third-party business partners to develop, promote and commercialize its drug candidates; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the COVID-19 pandemic on I-Mab's clinical development, commercial and other operations, as well as those risks more fully discussed in the "Risk Factors" section in I-Mab's most recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab, and I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

    Use of Non-GAAP Financial Measures

    To supplement its consolidated financial statements, which are presented in accordance with U.S. GAAP, the Company uses adjusted net income (loss) as a non-GAAP financial measure. Adjusted net income (loss) represents net income (loss) before share-based compensation. The Company's management believes that adjusted net income (loss) facilitates an understanding of operating results and provides management with a better capability to plan and forecast future periods. For more information on the non-GAAP financial measures, please see the table captioned "Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

    Non-GAAP information is not prepared in accordance with GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The presentation of this additional information should not be considered a substitute for GAAP results. A limitation of using adjusted net income (loss) is that adjusted net income (loss) excludes share-based compensation expense that has been and may continue to be incurred in the future.

    Exchange Rate Information

    This announcement contains the translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars are made at a rate of RMB7.2513 to US$1.00, the rate in effect as of June 30, 2023, published by the Federal Reserve Board of the United States.

    The translations of certain RMB amounts into U.S. dollars for historical periods presented in this announcement may not be identical to the ones previously announced by the Company. This is due to the differences in the particular exchange rate used by the Company for this announcement compared to historical exchange rates.

    For more information, please contact:

    Investors

    Media

    Tyler Ehler

    Gigi Feng

    Senior Director, Investor Relations

    Chief Communications Officer

    [email protected]

    [email protected]

     

     

    I-MAB

    Consolidated Balance Sheets

    (All amounts in thousands, except for share and per share data, unless otherwise noted)







    As of December 31,



    As of June 30,





    2022



    2023





    RMB



    US$



    RMB



    US$



















    Assets













    Current assets

















        Cash and cash equivalents



    3,214,005



    443,232



    2,359,592



    325,403

    Short-term restricted cash



    96,764



    13,344



    26,995



    3,723

    Short-term investments



    235,429



    32,467



    585,913



    80,801

    Prepayments and other receivables



    80,278



    11,071



    102,345



    14,113

    Total current assets



    3,626,476



    500,114



    3,074,845



    424,040

    Long-term restricted cash



    -



    -



    33,638



    4,639

    Property, equipment and software



    60,841



    8,390



    52,583



    7,252

    Operating lease right-of-use assets



    63,125



    8,705



    49,881



    6,879

    Intangible assets



    118,888



    16,395



    118,499



    16,342

    Goodwill



    162,574



    22,420



    162,574



    22,420

    Investments accounted for using the

    equity method



    30,850



    4,254



    11,411



    1,574

    Other non-current assets



    10,911



    1,505



    8,264



    1,140

    Total assets



    4,073,665



    561,783



    3,511,695



    484,286



















    Liabilities and shareholders' equity

















    Current liabilities

















    Short-term bank borrowings



    18,956



    2,614



    29,970



    4,133

    Accruals and other payables



    706,572



    97,440



    595,221



    82,085

    Operating lease liabilities, current



    23,961



    3,304



    27,322



    3,768

    Contract liabilities, current



    8,677



    1,197



    10,560



    1,456

    Total current liabilities



    758,166



    104,555



    663,073



    91,442

        Put right liabilities



    88,687



    12,230



    64,787



    8,935

    Contract liabilities, non-current



    267,878



    36,942



    267,644



    36,910

    Operating lease liabilities, non-current



    32,069



    4,423



    20,406



    2,814

    Other non-current liabilities



    16,963



    2,339



    49,002



    6,758

    Total liabilities



    1,163,763



    160,489



    1,064,912



    146,859



















    Shareholders' equity

















    Ordinary shares (US$0.0001 par value,

        800,000,000 shares authorized as of

        December 31, 2022, and June 30, 2023;

        190,879,919 and 190,033,689 shares

        issued and outstanding as of December

        31, 2022 and June 30, 2023, respectively)



    132



    18



    133



    18

    Treasury stock



    (21,249)



    (2,930)



    (46,017)



    (6,346)

    Additional paid-in capital



    9,579,375



    1,321,056



    9,751,140



    1,344,744

    Accumulated other comprehensive

    income



    213,794



    29,484



    376,473



    51,918

    Accumulated deficit



    (6,862,150)



    (946,334)



    (7,634,946)



    (1,052,907)

    Total shareholders' equity



    2,909,902



    401,294



    2,446,783



    337,427

    Total liabilities and shareholders' equity



    4,073,665



    561,783



    3,511,695



    484,286



















     

     

     

    I-MAB

    Consolidated Statements of Comprehensive Loss

     (All amounts in thousands, except for share and per share data, unless otherwise noted)





    For the six months ended June 30,



    2022



    2023



    RMB



    US$



    RMB



    US$

















    Revenues















    Licensing and collaboration revenue

    23,756



    3,276



    8,825



    1,217

    Supply of investigational products

    28,102



    3,875



    10,830



    1,494

    Total revenues

    51,858



    7,151



    19,655



    2,711

    Cost of revenues

    (27,237)



    (3,756)



    -



    -

    Expenses















    Research and development expenses (Note 1)

    (452,618)



    (62,419)



    (446,436)



    (61,566)

    Administrative expenses (Note 2)

    (392,460)



    (54,123)



    (244,991)



    (33,786)

    Loss from operations

    (820,457)



    (113,147)



    (671,772)



    (92,641)

    Interest income

    6,566



    905



    30,514



    4,208

    Interest expense

    -



    -



    (219)



    (30)

    Other expenses, net

    (51,944)



    (7,163)



    (71,701)



    (9,888)

    Equity in loss of affiliates (Note 3)

    (181,022)



    (24,964)



    (59,618)



    (8,222)

    Loss before income tax expense

    (1,046,857)



    (144,369)



    (772,796)



    (106,573)

       Income tax expense

    -



    -



    -



    -

    Net loss attributable to I-MAB

    (1,046,857)



    (144,369)



    (772,796)



    (106,573)

    Net loss attributable to ordinary shareholders

    (1,046,857)



    (144,369)



    (772,796)



    (106,573)

















    Net loss attributable to I-MAB

    (1,046,857)



    (144,369)



    (772,796)



    (106,573)

    Foreign currency translation adjustments, net of

    nil tax

    233,561



    32,210



    162,679



    22,434

    Total comprehensive loss attributable to I-MAB

    (813,296)



    (112,159)



    (610,117)



    (84,139)

















    Net loss attributable to ordinary shareholders

    (1,046,857)



    (144,369)



    (772,796)



    (106,573)

    Weighted-average number of ordinary shares used in

        calculating net loss per share - basic and diluted

    188,857,353



    188,857,353



    191,329,890



    191,329,890

    Net loss per share attributable to ordinary

        shareholders















    —Basic and diluted

    (5.54)



    (0.76)



    (4.04)



    (0.56)

    Net loss per ADS attributable to ordinary

        shareholders (Note 4)















    —Basic and diluted

    (12.74)



    (1.76)



    (9.29)



    (1.28)





    Notes:

    (1) Includes share-based compensation expense of RMB77,628 thousand (US$10,705 thousand) and RMB46,808 thousand

    (US$6,455 thousand) for the six months ended June 30, 2022 and 2023, respectively.

    (2) Includes share-based compensation expense of RMB119,314 thousand (US$16,454 thousand) and RMB88,006 thousand

    (US$12,137 thousand) for the six months ended June 30, 2022 and 2023, respectively.

    (3) Includes share-based compensation expense of RMB1,925 thousand (US$265 thousand) and RMB3,739 thousand (US$516

    thousand) for the six months ended June 30, 2022 and 2023, respectively.

    (4) Each ten ADSs represents twenty-three ordinary shares.

     

     

     

    I-MAB

    Reconciliation of GAAP and Non-GAAP Results







    For the six months ended June 30,





    2022



    2023





    RMB



    US$



    RMB



    US$



















    GAAP net loss attributable to I-MAB



    (1,046,857)



    (144,369)



    (772,796)



    (106,573)

    Add back:

















    Share-based compensation expense



    198,867



    27,424



    138,553



    19,108

    Non-GAAP adjusted net loss attributable

        to I-MAB



    (847,990)



    (116,945)



    (634,243)



    (87,465)



















    Non-GAAP adjusted loss attributable to

        ordinary shareholders



    (847,990)



    (116,945)



    (634,243)



    (87,465)

    Weighted-average number of ordinary

        shares used in calculating net loss per

        share – basic and diluted



    188,857,353



    188,857,353



    191,329,890



    191,329,890

    Non-GAAP adjusted loss per share

        attributable to ordinary shareholders

















    —Basic and diluted



    (4.49)



    (0.62)



    (3.31)



    (0.46)

    Non-GAAP adjusted loss per ADS

        attributable to ordinary shareholders

















    —Basic and diluted



    (10.33)



    (1.42)



    (7.61)



    (1.05)

     

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-provides-mid-year-2023-financial-results-business-and-corporate-updates-301903515.html

    SOURCE I-Mab

    Get the next $IMAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMAB

    DatePrice TargetRatingAnalyst
    12/9/2021$96.00Buy
    Siebert Williams Shank
    11/1/2021$83.00 → $85.00Buy
    Needham
    9/1/2021$75.00 → $95.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025

      ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract for a combination study of givastomig plus nivolumab and chemotherapy has been accepted for a mini-oral presentation at the ESMO Gastrointestinal Cancers Congress 2025, which will be held July 2-5 in Barcelona, Spain. "We are very pleased to receive confirmation that new clinical data for givastomig has been accepted as an oral presentation at the upcoming ESMO Gastrointestinal Cancers Congress 2025. As more information becomes available fr

      4/30/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

      Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

      4/3/25 4:01:00 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

      ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in 24th Annual Needham Virtual Healthcare Conference, being held April 7-10, 2025. Details are as follows: 24th Annual Needham Virtual Healthcare Conference Conference Date:April 7-10, 2025Format:Company Presentation and one-on-one meetingsPresentation Time:Monday, April 7, 2025, 8:45 to 9:25 AM ETWebcast Link:Register here   About I-Mab I-Mab (NASDAQ:IMAB) is a US-based, global biotech company, focused on the developm

      3/26/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    SEC Filings

    See more
    • SEC Form F-3 filed by I-MAB

      F-3 - I-Mab (0001778016) (Filer)

      5/2/25 5:01:56 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by I-MAB

      6-K - I-Mab (0001778016) (Filer)

      4/30/25 7:14:42 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by I-MAB

      6-K - I-Mab (0001778016) (Filer)

      4/4/25 4:59:51 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Financials

    Live finance-specific insights

    See more
    • I-Mab to Release Q3 2024 Financial Results on November 14, 2024

      ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year fin

      10/31/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

      Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027I-Mab will hold a conference call and webcast today, August 28th, at 8:00 AM ETROCKVILLE, Md., Aug. 28, 2024 /PRNews

      8/28/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab to Release 1H 2024 Financial Results on August 28, 2024

      Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

      8/14/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Siebert Williams Shank initiated coverage on I-Mab with a new price target

      Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00

      12/9/21 8:33:47 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on I-MAB with a new price target

      Needham reiterated coverage of I-MAB with a rating of Buy and set a new price target of $85.00 from $83.00 previously

      11/1/21 4:39:06 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on I-MAB with a new price target

      HC Wainwright & Co. reiterated coverage of I-MAB with a rating of Buy and set a new price target of $95.00 from $75.00 previously

      9/1/21 6:14:32 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by I-MAB (Amendment)

      SC 13G/A - I-Mab (0001778016) (Subject)

      2/13/24 11:26:50 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by I-MAB (Amendment)

      SC 13G/A - I-Mab (0001778016) (Subject)

      2/9/24 4:01:20 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by I-MAB

      SC 13D - I-Mab (0001778016) (Subject)

      12/1/23 2:41:06 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Leadership Updates

    Live Leadership Updates

    See more
    • I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

      Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

      4/3/25 4:01:00 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

      Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritizationThe Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study is now underway with data expected in early 2026Cash balance of $184.4 million (as of September 30, 2024), expected to support operations into 2027, complemented by a strengthened U.S.-based leadership team and streamlined operating modelROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based,

      1/6/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports Third Quarter 2024 Results

      Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended

      11/14/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care